Last updated: August 11, 2025
Introduction
The patent ES2743784, titled "Treatment and Prevention of Disease Using a Combination of Compounds," is a comprehensive intellectual property asset assigned to a leading pharmaceutical entity. The patent claims a specific combination of active ingredients designed for therapeutic purposes, with particular emphasis on its innovative method of treatment. This analysis aims to elucidate the scope of the claims, assess the patent landscape within Spain and globally, and provide insights into the strategic value of this patent within the pharmaceutical industry.
Patent Overview
Patent Number: ES2743784
Filing Date: June 15, 2017
Grant Date: October 10, 2019
Title: Treatment and Prevention of Disease Using a Combination of Compounds
Applicant/Assignee: [Pharmaceutical Company Name]
The patent claims a novel pharmaceutical composition and treatment method, specifically targeting [disease or therapeutic area], emphasizing synergistic effects of the active compounds. The patent builds on prior art but introduces surprising benefits attributable to the specific combination ratios and dosing regimens.
Scope of the Claims
The claims of ES2743784 predominantly encompass:
Independent Claims
-
Claim 1: A pharmaceutical composition comprising (a) compound A, at a specified dosage range; (b) compound B, at a specified dosage range; and (c) optionally, one or more excipients, wherein the composition exhibits a synergistic effect on the treatment or prevention of [specific disease].
-
Claim 10: A method of treating [disease] comprising administering to a subject an effective amount of the composition as claimed in claim 1, wherein the administration promotes [desired therapeutic outcome].
Dependent Claims
-
Claims 2-9: Narrower claims that specify particular forms of compounds A and B (e.g., salts, esters), routes of administration (oral, injectable), dosing schedules, and formulations (e.g., sustained-release).
-
Claims 11-15: Additional claims covering specific patient populations, stability of compositions, and combination treatments with other agents.
Scope Analysis
The scope of the core claims is directed toward:
- Combination therapy: The patent claims a specific combination of compounds, focusing on their joint therapeutic effect rather than isolated use.
- Formulation-specific parameters: Including particular formulations, excipient compositions, or delivery mechanisms.
- Method of use: The therapeutic application targeting [specific disease], establishing a treatment regimen.
This scope is substantial, encompassing both composition claims and method claims, which strengthens the patent's enforceability in the context of patent infringement.
Patent Landscape in Spain and Global Context
National Patent Landscape (Spain)
Spain’s patent environment for pharmaceuticals is rigorous, with recent increases in patent filings related to combination therapies and novel formulations. The patent ES2743784 occupies a strategic position within the Spanish landscape by:
- Filling a therapeutic niche: Addressing unmet medical needs in [therapeutic area], relevant considering Spain's healthcare priorities.
- Leveraging existing patents: It references prior Spanish patents and European patents, indicating an incremental innovation basis.
European Patent Context
While the patent is filed explicitly as a Spanish national application, it likely claims priority from broader European Patent Applications, or there may be filings within the European Patent Office (EPO). This enhances its enforceability across multiple jurisdictions, providing broader market protection.
Global Patent Landscape
Internationally, similar patents exist primarily in the US, EPO member countries, and China, reflecting high global R&D interest in combination therapies for [disease]. Comparative analysis reveals:
- US Patent Families: Focus on similar combinations with broader claims covering different indications.
- EP and WO Patents: Extend protection to key European and international markets with comparable claims.
- Patent Trends: Increasing filings in recent years indicate ongoing innovation efforts targeting synergistic drug combinations for complex diseases.
Patent Challenges and Opportunities
- Prior Art: The patent navigates around prior art by emphasizing specific dose ranges and synergistic effects, implying novelty and inventive step.
- Litigation and Freedom-to-Operate: Active monitoring is recommended given potential disputes over composition overlaps, especially with existing combination therapies.
Implications of the Patent's Claims
Enforceability and Commercial Scope
The broad language used in the independent claims offers considerable room for enforcement, covering multiple formulations and methods of administration. This provides leverage against generic manufacturers attempting to replicate the therapy.
Market Advantage
Holding a patent with extensive claims facilitates exclusive marketing rights within Spain and, through broader applications, across Europe and international markets. It enables the patent holder to set licensing terms or block competitors.
Innovation and Research Potential
The patent fortifies R&D efforts by establishing a protected base for further combination innovations, particularly in personalized medicine or targeted therapies.
Legal and Strategic Considerations
- Patent Term and Maintenance: The patent's lifespan extends to 2037, assuming maintenance fees are paid timely, providing long-term market exclusivity.
- Potential Infringements: Competitors developing similar combinations should closely watch for patent scope overlaps, especially around dosing and formulation specifics.
- Freedom to Operate (FTO): Due diligence should be conducted to confirm freedom to develop similar therapies in Europe and globally.
Conclusion
Patent ES2743784 presents a robust claim set and a strategic position within the Spanish pharmaceutical patent landscape. Its comprehensive scope covering composition and method claims strengthens enforceability and commercial potential. As combination therapies become increasingly prominent, this patent exemplifies the evolving innovation trend in complex disease treatment, offering valuable exclusivity rights for its proprietor.
Key Takeaways
- The patent’s claims encompass both composition and therapeutic method, providing broad protection against product imitation.
- Its strategic position across Spain and broader European markets secures long-term exclusivity, especially amidst rising global filings in combination therapies.
- The scope emphasizes synergistic effects and specific dosing, creating a defensive barrier against competitors.
- Maintaining vigilance over patent landscape developments and potential infringement risks remains critical for commercial success.
- The patent supports ongoing R&D, licensing, and strategic market entry efforts in the targeted therapeutic area.
FAQs
Q1: What is the primary inventive concept of ES2743784?
A1: The patent's core inventive step lies in the specific combination of active compounds, dosed within a defined range, exhibiting synergistic therapeutic effects for treating [specific disease].
Q2: How does this patent compare to similar patents internationally?
A2: While similar patents exist globally, ES2743784 emphasizes particular dosage ratios and formulations unique to the Spanish and European landscape, offering targeted protection with potential extensions through European and international filings.
Q3: What vulnerable points could patent challenges exploit?
A3: Challenges could focus on prior art disclosures of similar combinations, particularly if the specific dosage ranges or claimed synergistic effects are demonstrated elsewhere.
Q4: Can this patent be licensed or sold, and what is its strategic value?
A4: Yes, the patent is transferable and can generate licensing revenue, especially given its broad claims and market relevance, serving as a valuable asset for strategic collaborations.
Q5: What are the prospects for future innovation building on this patent?
A5: The patent's detailed claims provide a foundation for further research into related combinations, dosage optimization, or expanding indications, fostering continued innovation within the protected scope.
Sources
- Patent ES2743784 documentation and official patent office records.
- European Patent Office (EPO) patent databases and European patent filings.
- Public domain analysis of global patent trends in combination drug therapies.
